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Introduction
The Cox Maze (CM) procedure was originally developed by 
Dr. James Cox in 1987. After several revisions to its original 
lesion set, the Cox-Maze III (CMIII) became the gold 
standard in the surgical treatment of atrial fibrillation (AF). 
Initially, it was commonly performed only as a stand-alone 
procedure because of its technical complexity and long cross 
clamp time (1,2). As experience grew with the procedure, its 
use was more broadly applied and began to be performed in 
patients with concomitant mitral disease and other cardiac 
pathology. The overall freedom from symptomatic AF in 
patients who underwent CMIII has been reported to exceed 
90% in series with more than five years of follow-up (1,2).
To simplify the CMIII, different ablation technologies 
were studied in an attempt to reproduce the transmural 
lesions of the “cut-and-sew” method of the CMIII. 
This resulted in the development of the Cox-Maze 
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IV (CMIV) in 2002. The CMIV utilized a bipolar 
radiofrequency energy clamp to achieve continuous 
transmural ablations and replaced the majority of the 
“cut-and-sew” lesions of the CMIII (3). This method has 
proved to be as effective as the CMIII in long-term follow-up 
while decreasing cross clamp times. The CMIV has become 
the current standard procedure for the surgical treatment of 
AF at our institution (4). 
AF is present in up to a third of patients undergoing 
mitral valve (MV) procedures (5). While common, the 
mechanistic relationship between mitral regurgitation and 
AF is poorly understood, compared to patients with lone AF. 
Moreover, many of the early case series, including our own, 
concentrated on results in patients with lone AF (4). With 
the advent of the CMIV and its decreased operative times, 
over half of patients currently receiving a CMIV procedure 
are undergoing concomitant MV surgery, highlighting 
the significant role of AF procedures (5). Given that the 
CMIV operation is performed in a concomitant fashion the 
majority of the time, it is critical to evaluate outcomes in 
this population. The purpose of this study was to compare 
outcomes of the stand-alone CMIV procedure to the CMIV 
procedure with concomitant mitral procedure and identify 
risk factors for recurrence of AF.
Methods
This study was approved by the Washington University 
School of Medicine Institutional Review Board. Informed 
consent and permission for release of information was 
obtained from each participant. All data were entered 
prospectively into a longitudinal database maintained at our 
institution.
Patients
A total of 335 patients, from January 2002 to December 
of 2012, who received a CMIV procedure for AF as a 
stand-alone CMIV (n=151) or concomitantly with a MV 
procedure (n=184) were reviewed. The CMIV procedure 
has previously been described (3). All patients received 
pulmonary vein isolation (PVI), confirmed by exit block 
from each pulmonary vein, unless patients had a left 
atrial (LA) thrombus which precluded cardioversion or 
cardioversion was unsuccessful. The lesion set was similar 
among all patients except for the addition in 2005 of a 
superior LA lesion which connected the right and left 
superior pulmonary veins. This lesion effectively electrically 
isolated the entire posterior left atrium and created a “box-
lesion” set. A small set of patients (n=19) underwent a LA 
lesion set only. 
Patients were discharged on class I or III antiarrhythmic 
drugs and warfarin, unless contraindicated; antiarrhythmic 
agents were discontinued two months postoperatively if 
patients were in normal sinus rhythm. β-blockers or calcium 
channel blockers were not considered as antiarrhythmic drugs.
Study design
Demographics and perioperative variables including 
complications were compared between stand-alone CMIV 
and concomitant groups. Early atrial tachyarrhythmias 
(ATAs) were defined as any ATA documented within 
30 days. Patients were evaluated starting at three months for 
recurrent ATAs. Electrocardiographic data were obtained 
at 3, 6, 12, 24, and 48 months. Initially, this consisted of 
either ECG or 24-hour Holter monitoring. Starting in the 
2008, 24-hour continuous cardiac monitoring was routinely 
obtained in all patients (6). 
Late recurrence was defined as any episode of AF, 
atrial flutter or atrial tachycardia that lasted greater than 
30 seconds (6). Patients that required an interventional 
procedure were deemed permanent failures.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation (SD) or as median with range. Categorical 
variables are expressed as frequencies and percentages 
with outcomes compared using the χ2 or the Fisher exact 
test. Continuous outcomes were compared using the t-test 
for means of normally distributed continuous variables 
and the Mann-Whitney U nonparametric test for skewed 
distributions.
Twenty-four preoperative and perioperative variables 
were evaluated by univariate analysis to identify predictors 
of AF recurrence at one year. Variables used in univariate 
analyses included the presence of a concomitant procedure 
in addition to those listed in Tables 1 and 2, with the 
exception of mortality, intensive care unit (ICU) and 
hospital length of stay (LOS). Significant covariates 
on univariate analysis (P≤0.10) or covariates deemed 
clinically relevant based on experience were entered into 
a multivariate binary logistic regression analysis. All data 
analyses were performed using SYSTAT 13 software (Systat 
Software, Inc., Chicago, IL).
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Results
A total of 151 patients (45%) underwent stand-alone CMIV 
procedure and 184 (55%) underwent the CMIV with a 
concomitant MV operation. MV operations included patients 
receiving a MV repair (111 patients, 60%) or MV replacement 
(73 patients, 40%). Twenty-nine patients receiving a mitral 
operation also underwent a tricuspid valve procedure (Table 3). 
Follow-up was available on 72% of patients at one year and 
55% of these at two years. Twenty-four hours of continuous 
monitoring was performed in 75% of patients who had follow-
up after 2008 (6). Mean follow-up time was 2.7±2.4 years.
Demographics
Demographics showed significant preoperative differences 
in terms of age, gender, AF duration, type of AF, NYHA 
classification, presence of failed catheter ablation and 
LA diameter between the two groups (Table 1). Notably, 
patients with MV disease had a longer documented 
duration of AF by 20 months and a higher incidence of 
longstanding persistent AF. Ejection fraction was similar 
between concomitant and stand-alone CMIV groups (53% 
vs. 52%, P=0.451) despite a greater percentage of patients 
with NYHA class III or IV symptoms in the concomitant 
group (71% vs. 30%, P<0.001).
Perioperative outcomes
Perioperative differences including complications and 
30-day mortality can be seen in Table 2. As expected, 
cardiopulmonary bypass (CPB) time was significantly 
longer in the concomitant group (189 vs. 133 min, 
P<0.001) as was cross clamp time (93 vs. 45 min, P<0.001). 
Major complications were defined as the development of 
pneumonia, mediastinitis, need for an intraaortic balloon 





CMIV + MV 
(n=184) 
P-value 
Age (years) 57±10 65±12 <0.001 
Male gender (%) 73 43 <0.001 
AF duration (months) 89±77 69±80 0.002 
Paroxysmal AF (%) 27 43 0.002 
Persistent AF (%) 7 13 0.055 
Longstanding  
persistent AF (%) 
66 43 <0.001 
NYHA III or IV (%) 30 71 <0.001 
LVEF (%) 52±12 53±11 0.451 
Failed cath  
ablation (%) 
49 9 <0.001 
Preop pacemaker (%) 11 12 0.744 
LA diameter (cm) 4.8±1 5.5±1.2 <0.001
a, continuous variables are listed as mean ± standard 
deviation; CMIV, Cox-Maze IV; MV, mitral valve; AF, atrial 
fibrillation; LA, left atrial; LVEF, left ventricular ejection 
fraction.




CMIV + MV 
(n=184)
P-value
Box-lesion (%) 86 87 0.704 
Cardiopulmonary 
bypass time (min) 
133±31 189±41 <0.001 
Cross clamp  
time (min) 
45±18 93±29 <0.001 
Early ATA (%) 48 63 0.004 
Permanent  
pacemaker (%) 
5 11 0.026 
Overall major 
complicationb 
9 (6%) 29 (16%) 0.005 
Pneumonia 6 (4%) 15 (8%) 0.120 
Mediastinitis 1 (0.6%) 1 (0.5%) 0.885 
Intraaortic balloon  
pump
0 (0%) 5 (3%) 0.042 
Permanent Stroke 1 (0.6%) 1 (0.5%) 0.885 
Reoperation for 
bleeding
0 (0%) 9 (5%) 0.006 
Renal failure requiring 
dialysis
1 (6%) 9 (5%) 0.24 
Median ICU LOS  
in days (range) 
2 [1-35] 3 [1-61] <0.001 
Median hospital LOS  
in days (range) 
8 [4-53] 9 [1-111] <0.001 
30-day mortality (%) 1 (1%) 10 (5%) 0.015 
a, continuous variables are listed as mean ± standard 
deviation; b, complications are listed as total number (%); 
CMIV, Cox-Maze IV; MV, mitral valve; AF, atrial fibrillation; 
ATA, atrial tachyarrhythmia; ICU, intensive care unit; LOS, 
length of stay.
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renal failure requiring dialysis. Comparisons of the overall 
major complication rate as well as individual complications 
were performed. The overall major complication rate was 
higher in the concomitant group (16% vs. 6%, P=0.005), 
with significant differences between the need for an IABP (3% 
vs. 0%, P=0.042) and reoperation for bleeding (5% vs. 0%, 
P=0.006). Early post-operative ATAs were more frequent in 
the concomitant group (63% vs. 48%, P=0.004).
Median ICU LOS was decreased in the stand-alone 
CMIV group (2% vs. 3%, P<0.001) as was median hospital 
length of LOS (8% vs. 9%, P<0.001). There was a lower 
rate of 30-day mortality in the stand-alone CMIV group 
(1% vs. 5%, P<0.015).
Efficacy
Freedom from ATA after a stand-alone CMIV procedure 
was 93%, 93%, 85%, and 82% at 3, 6, 12, and 24 months 
respectively. Freedom from ATA and antiarrhythmic drugs 
was lower at each time point, but the differences decreased 
with increasing follow-up (Figure 1). When performing 
a concomitant CMIV in addition to a MV procedure, 
freedom from ATA was 89%, 88%, 88%, and 90% at 3, 6, 
12, and 24 months respectively (Figure 2). Comparisons 
between the two groups showed no significant differences 
after six months (Figure 3).
Multivariate analysis
In all patients, predictors of recurrence were having a 
preoperative pacemaker (P<0.001), failure to perform a 
box-lesion (P=0.001), and early ATAs (P<0.001). In the 
stand-alone CMIV group, having a preoperative pacemaker 
(P=0.031) and early ATA (P=0.009) were the only two 
predictors of recurrence. In the concomitant CMIV group, 
having a preoperative pacemaker (P=0.011), failure to 
perform isolation of the pulmonary veins with a box-lesion 
(P=0.033) and early ATA (P=0.016) were all predictors of 
recurrence.
Discussion
In this study, perioperative outcomes and late efficacy were 
Table 3 Type of concomitant CMIV and MV procedure 
Concomitant operation Number performed (n=184)
CMIV + MV repair 91
CMIV + MV repair + TVR 19
CMIV + MV repair + CABG 1
CMIV + MVR 61
CMIV + MVR + TVR 10
CMIV + MVR + Other a 2
a, one patient received a septal myectomy and one patient 
received right ventricular assist device; CMIV, Cox-Maze IV; 
MV, mitral valve; CABG, coronary artery bypass graft; MVR, 
mitral valve replacement; TVR, tricuspid valve repair.
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compared between patients having a stand-alone CMIV and 
those having concomitant mitral surgery. Previous studies 
from our institution and others usually have compared the 
stand-alone Cox-Maze procedure to a combined cohort 
of patients receiving a Cox-Maze procedure in addition to 
multiple concomitant procedures, including coronary artery 
bypass grafting, aortic valve replacement, and MV repair 
(2,7). Because the diseases prompting these concomitant 
operations are the result of multiple heterogenous 
pathologies, it is difficult to interpret the results from a 
single “concomitant” cohort. It was for this reason that this 
study was designed to compare outcomes in patients with 
lone AF to those with AF and concomitant mitral disease. 
This comparison is important for two reasons. First of all, 
AF ablation is performed much more commonly in the 
setting of concomitant mitral disease than for lone AF. In 
a recent study, five times as many surgical ablations were 
performed in the US in patients undergoing mitral surgery 
than for lone AF (5). Second, patients with MV disease 
often have enlarged LA from either chronic volume or 
Figure 2 Two-year follow-up showing freedom from AF both on and off antiarrhythmic drugs after a concomitant CMIV + MV procedure. 
CMIV, Cox-Maze IV; MV, mitral valve; AF, atrial fibrillation.
Figure 3 Two-year follow-up comparing freedom from AF off antiarrhythmic drugs after a stand-alone Cox-Maze IV procedure and a 
concomitant CMIV + MV procedure. At six months, P=0.034 when comparing lone CMIV to concomitant CMIV + mitral operation. At all 
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pressure overload. This may result in different mechanisms 
of AF in this population, which could impair procedural 
success. Studies have shown that LA diameter is a risk factor 
for late recurrence of AF after a Cox-Maze procedure (8). 
In our study, the efficacy of the CMIV for both stand-
alone AF and when combined with a MV procedure was 
similar with respect to freedom from AF and antiarrhythmic 
agents at both one and two years. This is in agreement with 
our previous data showing comparable efficacy at one year 
using either the CMIII or the CMIV procedure, and shows 
that these good results were maintained at two years (2,9). 
As expected, the two groups had different demographics. 
Patients who received stand-alone CMIV procedure tended 
to be predominantly male, younger and had a higher 
incidence of longer standing persistent AF. Moreover, half 
of the patients had failed a previous catheter ablation. The 
concomitant group on the other hand had more patients 
with NYHA class III or IV symptoms and significantly 
larger LAs. Despite these differences, the efficacy of the 
CMIV was similar in both groups, highlighting the efficacy 
of the CMIV procedure for the treatment of AF in both 
populations.
Not surprisingly, there was a significant difference 
in the perioperative morbidity, mortality and 30-day 
mortality between the groups. In a previous report from 
our institution, 30-day mortality was not significant (9). 
However, the total number of patients in this study was 
increased by 57% compared to our previous publication. 
Major complication rates were also significantly 
increased in the concomitant group, primarily because 
of the need for reoperation for bleeding and an IABP. 
This is consistent with the fact that patients undergoing 
concomitant MV surgery were older, sicker and had longer 
cross clamp and CPB times. This increase in overall 
complication rate likely accounts for the one day increase 
in both ICU and hospital LOS. 
The multivariate analysis of risk factors for recurrent 
ATA in this large cohort of over 350 patients was 
informative. In agreement with prior studies from our 
group, the failure to perform a box-lesion around the 
pulmonary veins and posterior left atrium was a predictor 
of recurrence. The increased risk of recurrence seen with 
a preoperative pacemaker is a new observation and is likely 
due to the improved power of this study in detecting smaller 
differences in outcomes. Since the majority of pacemakers 
were implanted for sick sinus syndrome, this finding 
suggests that patients with intrinsic sinus node dysfunction 
may have higher recurrence rates, possibly due to the 
known increased incidence of premature atrial contractions 
in these patients which can act as a trigger for recurrent AF. 
The presence of early postoperative ATA as a predictor 
of late recurrence was in agreement with previous reports in 
the literature (8,10). This finding suggests that part of the 
substrate for early and late ATA may be similar. However 
this finding needs to be put into perspective. In patients 
undergoing concomitant MV and CMIV procedures, early 
ATA were present in 63% of patient but at two years only 
10% of patients had recurrent ATA. Thus, it is important 
to remember that the majority of patients with early ATA 
remain free of ATA at two years.
Surprisingly, LA size was not a predictor in this 
multivariate analysis in contradiction to other studies which 
have shown this to be an important variable for failure 
(10,11). This may have been due to the introduction of 
the box-lesion set. In these patients, isolation of the entire 
posterior LA may effectively decrease LA size from an 
electrophysiological standpoint and reduce the substrate 
available for maintaining AF, thus negating the effect of an 
enlarged left atrium.
This study has several limitations. While the majority 
of our patients did have 24-hours of continuous cardiac 
monitoring after six months, there were still some who 
only had ECGs leading to a possible underestimation in 
the incidence of recurrent AF. In addition, this study was 
a retrospective review which introduces inherent selection 
biases, that could potentially be avoided if performed in 
a randomized fashion. However, all data were collected 
prospectively and this was a series of consecutive patients. 
While this series did show that efficacy was maintained at 
two years, it did not determine whether failures were due to 
an inability to properly complete the lesion set or because 
the underlying mechanism of AF in these patients was not 
able to be eliminated with a Cox-Maze procedure. It is our 
impression that failures occur because of advanced atrial 
remodeling and subsequent substrate modification such 
as atrial fibrosis. In this setting, reentry can be sustained 
in very small areas of atria, making it virtually impossible 
to eliminate AF with a Cox-Maze procedure (12). Finally, 
the AF burden was not quantitated in this study. Future 
studies using implantable loop recorders (ILRs) are worth 
considering to provide this information.
In conclusion, patients receiving a CMIV procedure 
have high rates of freedom from AF at one and two years 
regardless of the addition of a MV procedure. Perioperative 
complications were increased in patient undergoing 
concomitant MV surgery resulting in a longer hospital stay 
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and higher 30-day mortality. Further advances in surgical 
techniques such as minimally invasive approaches may help 
to offset these differences. 
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